ARIZ Precision Medicine develops targeted siRNA therapies that address the genetic and epigenetic errors driving cancer growth. By utilizing a precision medicine approach combined with nanotechnology, the company delivers drugs specifically to cancer cells, minimizing damage to healthy tissues.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer therapies lack specificity, leading to systemic toxicity and damage to healthy tissues. Targeting the underlying genetic and epigenetic errors that drive cancer growth remains a challenge. Effective drug delivery to cancer cells, while sparing normal cells, is a critical unmet need.
Solution
ARIZ Precision Medicine is developing targeted siRNA therapies designed to address the genetic and epigenetic errors that initiate and drive cancer growth. The company employs a precision medicine approach, combining biological and nanotechnologies to deliver drugs specifically to cancer cells. This targeted delivery aims to minimize off-target effects and reduce damage to healthy tissues, improving patient outcomes. By focusing on the root causes of cancer at the molecular level, ARIZ Precision Medicine seeks to prevent cancer growth and metastasis.
Target Audience
The primary target audience includes oncology researchers, clinicians, and pharmaceutical companies focused on developing more effective and less toxic cancer treatments.
Features
- siRNA-based therapeutics targeting specific genetic and epigenetic errors in cancer cells
- Nanotechnology-based drug delivery system for targeted delivery to tumors
- Ligand-targeted approach to enhance drug uptake by cancer cells
- Designed to minimize off-target effects and systemic toxicity
- Aims to prevent cancer growth and metastasis by addressing root causes